What is the success rate of stem cell therapy for Muscular Dystrophy?
No pooled stem-cell success rate applies across different muscular dystrophies or products. Review the exact genotype, age and disease-stage criteria, comparator, motor and respiratory endpoints, loss to follow-up, serious adverse events and absolute effect.
What the evidence shows for Muscular Dystrophy
Some gene-based and pharmacological treatments are authorised for defined muscular-dystrophy subtypes and eligibility criteria, while many cell approaches remain preclinical or early clinical research. The 2025 NIH muscular-dystrophy research plan stresses subtype-specific evidence, safety, durability and post-authorisation monitoring. Evidence from one dystrophy, vector or gene product cannot validate a commercial stromal-cell or exosome offer.
Am I a candidate? → · Muscular Dystrophy: full overview → · Muscular Dystrophy cost → · Cost →
Evidence checked against ISSCR, FDA and EMA guidance. See our editorial standards. This is information, not medical advice. Educational information, not medical advice; figures indicative.